Urgent Medical Device Safety Notification
Use of Unapproved Drugs with the SynchroMed® Implantable Infusion Pump

Dear Healthcare Professional,

This letter provides important updated information on Medtronic Neuromodulation’s continuing efforts to investigate and communicate the impact of unapproved drugs on the performance of the SynchroMed infusion pump system. Use of unapproved drugs with SynchroMed pumps can result in an increased risk of permanent motor stall and cessation of drug infusion. Approved drugs for use with the SynchroMed infusion systems are Infumorph®, Lioresal®, Prialt® (Ziconotide), Floxuridine, Methotrexate and Gablofen®. More drug detail is attached to this letter in the Summary of Approved Drugs.

Explanation of the Issue:
Based on data from Medtronic’s Implantable Systems Performance Registry (ISPR), the overall failure rate of the SynchroMed II pump at 78 months post implant is 2.4% when used to dispense approved drugs, and 7.0% when used to dispense unapproved drugs. The use of unapproved drugs can lead to intermittent or permanent pump motor stalls which may be reported as a loss of or change in therapy. Therapy changes could potentially result in serious injury and/or death. Pumps can experience motor stalls when used with either approved or unapproved drugs, however pump motor stalls have been reported at a significantly lower rate when approved drugs are exclusively used.

Medtronic continues to investigate motor gear corrosion, which has been identified as a primary contributor to permanent motor stall in both SynchroMed II and SynchroMed EL pumps. Enclosed you will find a document titled Increased Risk of Motor Stall and Loss of or Change in Therapy with Unapproved Drug Formulations that provides additional details.

Recommendations:
To minimize the potential for motor stall, only use the approved drugs that are identified in the SynchroMed infusion system labeling or drugs approved by FDA that are labeled for use with the SynchroMed II pump. Do not use compounded drugs, unapproved concentrations or unapproved formulations.

- Continue to monitor patients closely for the possible return of baseline symptoms. A return of baseline symptoms could potentially indicate pump damage.
- Reinforce with patients and caregivers information on the signs and symptoms of withdrawal due to therapy cessation, and the importance of contacting their healthcare provider immediately if these signs and symptoms appear.
- The SynchroMed II pump is designed with a critical alarm for pump motor stall. For patients implanted with a SynchroMed II pump, you can change the critical alarm interval frequency to sound every 10 minutes.
  - Remind patients, their caregivers, and your appropriate staff members to be alert for pump alarms.
  - At implant or follow-up visits, perform an alarm test to provide an opportunity for patients and caregivers to hear and differentiate between the critical and non-critical pump alarms.
  - For patients with a Personal Therapy Manager (PTM), the PTM will show alarm code 8476 when a bolus is attempted if there is an active alarm.
- Retrieve logs when interrogating the SynchroMed II pump in order to check for motor stall events. Note that a temporary motor stall with recovery is expected behavior when the pump is exposed to a strong magnetic field such as during an MRI. Medtronic Technical Services can be contacted for further assistance evaluating motor stall events on logs.
**Additional Information:**
We are committed to continuing to advance the practice of intrathecal drug delivery and to improve our product performance and services to enable you to manage your patients in a safe and effective manner. You can access product performance information online at: [http://professional.medtronic.com](http://professional.medtronic.com).

If you have questions please contact Medtronic Neuromodulation Technical Services at 1-800-707-0933 weekdays 7am - 6pm CST. Please report any malfunction or adverse event related to a device to Medtronic Neuromodulation Technical Services and to FDA’s MedWatch Program ([www.fda.gov/medwatch](http://www.fda.gov/medwatch)).

Sincerely,

![Signature]

Jill Smith  
Vice President Quality  
Medtronic Neuromodulation

**Enclosures:**
- Increased Risk of Motor Stall and Loss of or Change in Therapy with Unapproved Drug Formulations
- Summary of Approved Drugs
- Physician Reply Card